Oligoastrocytoma
diseaseOn this page
Also known as glioma, mixed, benignmixed astrocytic-oligodendroglial neoplasmmixed astrocytic-oligodendroglial tumormixed astrocytic-oligodendroglial tumourmixed astrocytoma-oligodendrogliomamixed oligo-astrocytomamixed oligoastrocytomamixed oligodendroglioma-astrocytomaMOAWHO grade II mixed glioma
Summary
Oligoastrocytoma (MONDO:0016702) is a disease and 24 clinical trials. Top therapeutic interventions include temozolomide, etoposide phosphate, and mannitol. A subtype of mixed glioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 24
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | oligoastrocytoma |
| Mondo ID | MONDO:0016702 |
| EFO | EFO:0000630 |
| Orphanet | 251656 |
| DOID | DOID:7912 |
| NCIT | C4050 |
| SNOMED CT | 716647001 |
| UMLS | C0547065 |
| MedGen | 154285 |
| GARD | 0009769 |
| MedDRA | 10027744 |
| Is cancer (heuristic) | no |
Also known as: glioma, mixed, benign · mixed astrocytic-oligodendroglial neoplasm · mixed astrocytic-oligodendroglial tumor · mixed astrocytic-oligodendroglial tumour · mixed astrocytoma-oligodendroglioma · mixed oligo-astrocytoma · mixed oligoastrocytoma · mixed oligodendroglioma-astrocytoma · MOA · oligoastrocytoma · WHO grade II mixed glioma
Data availability: 3 cell lines.
Disease family
This is a subtype of mixed glioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › nervous system neoplasm › neuroepithelial neoplasm › glioma › mixed glioma › oligoastrocytoma
Related subtypes (2): mixed astrocytoma-ependymoma-oligodendroglioma, mixed astrocytoma-ependymoma
Subtypes (1): anaplastic oligoastrocytoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Temozolomide | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Bevacizumab, Carboplatin, Doxorubicin, Etoposide, Everolimus, Palbociclib, Vandetanib.
Clinical trials & evidence
Clinical trials
Clinical trials: 24.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 7 |
| PHASE1 | 5 |
| Not specified | 5 |
| PHASE1/PHASE2 | 4 |
| PHASE3 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00717210 | PHASE3 | COMPLETED | Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide |
| NCT00897377 | PHASE3 | TERMINATED | Treatment Strategy for Low-grade Gliomas |
| NCT03180502 | PHASE2 | ACTIVE_NOT_RECRUITING | Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma |
| NCT04623931 | PHASE2 | RECRUITING | Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas |
| NCT00024570 | PHASE1/PHASE2 | COMPLETED | Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma |
| NCT00041587 | PHASE1/PHASE2 | COMPLETED | Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma |
| NCT00303849 | PHASE1/PHASE2 | COMPLETED | Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors |
| NCT00389090 | PHASE2 | TERMINATED | A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma |
| NCT01884740 | PHASE1/PHASE2 | TERMINATED | Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 |
| NCT02023905 | PHASE2 | TERMINATED | Everolimus With and Without Temozolomide in Adult Low Grade Glioma |
| NCT02209428 | PHASE2 | UNKNOWN | A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas |
| NCT02372409 | PHASE2 | TERMINATED | Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors |
| NCT02530320 | PHASE2 | COMPLETED | Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved |
| NCT03152318 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 |
| NCT07031765 | PHASE1 | ACTIVE_NOT_RECRUITING | Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma |
| NCT00024557 | PHASE1 | COMPLETED | Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients |
| NCT00064779 | PHASE1 | COMPLETED | Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma |
| NCT00089427 | PHASE1 | COMPLETED | IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma |
| NCT00874861 | EARLY_PHASE1 | COMPLETED | HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas |
| NCT01089244 | Not specified | UNKNOWN | FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma |
| NCT01281982 | Not specified | TERMINATED | (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas |
| NCT01849952 | Not specified | TERMINATED | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas |
| NCT02903784 | Not specified | COMPLETED | Neural Basis of Language Processing |
| NCT03353896 | Not specified | WITHDRAWN | NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TEMOZOLOMIDE | 4 | 2 |
| ETOPOSIDE PHOSPHATE | 4 | 1 |
| MANNITOL | 4 | 1 |
| PALBOCICLIB | 4 | 1 |
| SODIUM THIOSULFATE | 4 | 1 |
| SORBITOL | 4 | 1 |
| CINTREDEKIN BESUDOTOX | 3 | 5 |
| 6-O-BENZYLGUANINE | 3 | 1 |
| HILTONOL | 2 | 1 |
| CHEMBL4228794 | 0 | 7 |
| CHEMBL4248195 | 0 | 2 |
| CHEMBL3753202 | 0 | 1 |
| CHEMBL365847 | 0 | 1 |